NCT05350592View on ClinicalTrials.gov

Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

March 13, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions

Acute Myocardial InfarctionCardiogenic Shock

Interventions

DRUG

Tocilizumab

Single bolus

DRUG

Dobutamine

Continous weight-adjusted infusion

DRUG

NaCl 0.9%

Placebo comparator and diluent

Trial Locations (1)

2100

Rigshospitalet, Copenhagen University Hospital, Copenhagen

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

Simon Spies Fonden

UNKNOWN

collaborator

Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat

UNKNOWN

lead

Rigshospitalet, Denmark

OTHER

NCT05350592 - Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock | Biotech Hunter | Biotech Hunter